MiR-155-targeted IcosL controls tumor rejection.

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Elevated microRNA-155 (miR-155) levels are linked to increased aggressiveness in various cancers.
• miR-155's role in immune evasion within the tumor microenvironment requires further elucidation.

Purpose of the Study:

• To investigate the mechanism by which miR-155 influences anti-tumor immunity.
• To explore the therapeutic potential of targeting the miR-155/IcosL axis in cancer treatment.

Main Methods:

• Utilized genetically engineered mouse models (Eµ-miR-155 and Cre-Tet-OFF systems) to study miR-155 function in B-cell malignancies.
• Assessed the impact of miR-155 on IcosL expression in tumor cells and immune infiltrates.
• Engineered MC38 colon cancer cells to overexpress IcosL and evaluated anti-tumor effects in vivo.

Main Results:

• miR-155 overexpression in B-cell lymphomas led to a loss of IcosL expression.
• Induction of miR-155 in tumors resulted in malignant cells lacking IcosL, while its suppression promoted tumor regression and immune cell infiltration.
• Engineering cancer cells to express IcosL enhanced CD8+ T cell infiltration and reduced tumor growth.

Conclusions:

• miR-155 impairs anti-tumor immunity by targeting IcosL, thereby inhibiting cytotoxic T-cell infiltration.
• Restoring or increasing IcosL expression on malignant cells can enhance anti-tumor immune responses.
• Targeting the miR-155/IcosL pathway presents a promising strategy for developing novel cancer immunotherapies.